SCHEMBL374388

SCHEMBL374388

NC(=O)Nc1c(Cl)cc(Cl)cc1Cl

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.48
ALDH1A1 P00352 4/20 0.46
RAB9A P51151 2/20 0.46
MAPT P10636 2/20 0.46
MEN1 O00255 1/20 0.46
POLB P06746 1/20 0.46
MAPK1 P28482 1/20 0.46
KMT2A Q03164 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44
LMNA P02545 2/20 0.41
HPGD P15428 1/20 0.41
GAA P10253 1/20 0.41
HTT P42858 1/20 0.39
CYP3A4 P08684 1/20 0.39
TSHR P16473 1/20 0.39
RECQL P46063 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11091737 0.81 ALDH1A1 (0.40) NPC1ALDH1A1RAB9AMAPTMEN1
SCHEMBL11461967 0.80 TSHR (0.43) ALDH1A1MAPTMEN1MAPK1KMT2A
SCHEMBL11547021 0.79 CA5A (0.39) NPC1ALDH1A1RAB9AMAPTMEN1
SCHEMBL2094463 0.79 ALDH1A1 (0.47) NPC1ALDH1A1RAB9AMAPTMEN1
SCHEMBL9837096 0.79 ALDH1A1 (0.47) NPC1ALDH1A1RAB9AMAPTMEN1
SCHEMBL2094466 0.79 ALDH1A1 (0.51) NPC1ALDH1A1RAB9AMAPTMEN1
SCHEMBL11426891 0.78 NPC1 (0.41) NPC1ALDH1A1MAPTMAPK1CA1
SCHEMBL28513984 0.78 NT5E (0.44) NPC1RAB9APOLBL3MBTL1CA12
SCHEMBL4303962 0.78 CA12 (0.42) NPC1ALDH1A1RAB9AMAPTMEN1
SCHEMBL11883596 0.77 ALDH1A1 (0.39) NPC1ALDH1A1RAB9AMAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115850123-B Preparation method of 2, 4-dichloroaniline/hydrazine 山东潍坊润丰化工股份有限公司 2024-04-19 CN claimed
CN-115850123-A Preparation method of 2, 4-dichloroaniline/hydrazine 山东潍坊润丰化工股份有限公司 2023-03-28 CN claimed
CN-107922326-A The Preparation Method And Their Intermediate of Apremilast 雷迪博士实验室有限公司 2018-04-17 CN claimed
WO-2014053709-A1 A METHOD FOR CULTURING STEM CELLS GLYKOS FINLAND OY (FI) 2014-04-10 WO claimed
EP-2408903-A1 CULTURE OF PLURIPOTENT AND MULTIPOTENT CELLS ON MICROCARRIERS Agency For Science, Technology And Research (SG) 2012-01-25 EP claimed
WO-2010107392-A1 CULTURE OF PLURIPOTENT AND MULTIPOTENT CELLS ON MICROCARRIERS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2010-09-23 WO claimed
WO-2004087669-A1 NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO. LTD. (JP) 2004-10-14 WO claimed
CN-115850123-B Preparation method of 2, 4-dichloroaniline/hydrazine 山东潍坊润丰化工股份有限公司 2024-04-19 CN disclosed
EP-4337675-A1 ANGIOTENSIN-(1-9) ANALOGUE BASED ON D AMINO ACIDS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF Universidad De Chile (CL) 2024-03-20 EP disclosed
CN-115850123-A Preparation method of 2, 4-dichloroaniline/hydrazine 山东潍坊润丰化工股份有限公司 2023-03-28 CN disclosed
CN-107922326-A The Preparation Method And Their Intermediate of Apremilast 雷迪博士实验室有限公司 2018-04-17 CN disclosed
CN-107614678-A Methods for producing β cells derived from stem cells and methods of use thereof 哈佛学院校长同事会 2018-01-19 CN disclosed
CN-107075469-A Mammal limbal stem cell, its production method and its purposes of culture 加利福尼亚大学董事会 2017-08-18 CN disclosed
EP-1737830-A1 TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS The Procter and Gamble Company (US) 2007-01-03 EP disclosed
WO-2005105757-A1 TRI-SUBSTITUTED UREAS AS CYTOKINE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2005-11-10 WO disclosed
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof TAISHO PHARMACEUTICAL CO., LTD. 2005-09-08 US disclosed
WO-2004087669-A1 NOVEL QUINOLINE, TETRAHYDROQUINAZOLINE, AND PYRIMIDINE DERIVATIVES AND METHODS OF TREATMENT RELATED TO THE USE THEREOF TAISHO PHARMACEUTICAL CO. LTD. (JP) 2004-10-14 WO disclosed
EP-0438209-B1 Uracil derivatives and pesticides containing the same as active ingredient NISSAN CHEMICAL IND LTD (JP) 1994-09-21 EP disclosed
US-5116404-A URACIL DERIVATIVES AND PESTICIDES CONTAINING THE SAME AS ACTIVE INGREDIENT NISSAN CHEMICAL INDUSTRIES LTD. (JP) 1992-05-26 US disclosed
EP-0438209-A1 Uracil derivatives and pesticides containing the same as active ingredient NISSAN CHEMICAL INDUSTRIES, LIMITED (JP) 1991-07-24 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197350-A1 Novel quinoline, tetrahydroquinazoline, and pyrimidine derivatives and methods of treatment related to the use thereof HCRTR2, MCHR1, MCHR2 NPC1 778/4885ALDH1A1 2036/4885RAB9A 1648/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.